A. baumannii

''Acinetobacter baumannii'' is a typically short, almost round, rod-shaped (coccobacillus) Gram-negative bacterium. It is named after the bacteriologist Paul Baumann. It can be an opportunistic pathogen in humans, affecting people with compromised immune systems, and is becoming increasingly important as a hospital-derived (nosocomial) infection. While other species of the genus ''Acinetobacter'' are often found in soil samples (leading to the common misconception that ''A. baumannii'' is a soil organism, too), it is almost exclusively isolated from hospital environments. Although occasionally it has been found in environmental soil and water samples, its natural habitat is still not known.

Bacteria of this genus lack flagella, whip-like structures many bacteria use for locomotion, but exhibit twitching or swarming motility. This may be due to the activity of type IV pili, pole-like structures that can be extended and retracted. Motility in ''A. baumannii'' may also be due to the excretion of exopolysaccharide, creating a film of high-molecular-weight sugar chains behind the bacterium to move forward. Clinical microbiologists typically differentiate members of the genus ''Acinetobacter'' from other Moraxellaceae by performing an oxidase test, as ''Acinetobacter'' spp. are the only members of the Moraxellaceae to lack cytochrome c oxidases.

''A. baumannii'' is part of the ACB complex (''A. baumannii'', ''A. calcoaceticus'', and ''Acinetobacter'' genomic species 13TU). It is difficult to determine the specific species of members of the ACB complex and they comprise the most clinically relevant members of the genus. ''A. baumannii'' has also been identified as an ESKAPE pathogen (''Enterococcus faecium'', ''Staphylococcus aureus'', ''Klebsiella pneumoniae'', ''Acinetobacter baumannii'', ''Pseudomonas aeruginosa'', and ''Enterobacter'' species), a group of pathogens with a high rate of antibiotic resistance that are responsible for the majority of nosocomial infections.

Colloquially, ''A. baumannii'' is referred to as "Iraqibacter" due to its seemingly sudden emergence in military treatment facilities during the Iraq War. It has continued to be an issue for veterans and soldiers who served in Iraq and Afghanistan. Multidrug-resistant ''A. baumannii'' has spread to civilian hospitals in part due to the transport of infected soldiers through multiple medical facilities. During the COVID-19 pandemic, coinfection with ''A. baumannii'' secondary to SARS-CoV-2 infections has been reported multiple times in medical publications.

OmpA

Adhesion can be a critical determinant of virulence for bacteria. The ability to attach to host cells allows bacteria to interact with them in various ways, whether by type III secretion system or simply by holding on against the prevailing movement of fluids. Outer membrane protein A (OmpA) has been shown to be involved in the adherence of ''A. baumannii'' to epithelial cells. This allows the bacteria to invade the cells through the zipper mechanism. The protein was also shown to localize to the mitochondria of epithelial cells and cause necrosis by stimulating the production of reactive oxygen species.

Antibiotic resistance

Mechanisms of antibiotic resistance can be categorized into three groups. First, resistance can be achieved by reducing membrane permeability or increasing efflux of the antibiotic and thus preventing access to the target. Second, bacteria can protect the antibiotic target through genetic mutation or post-translational modification, and last, antibiotics can be directly inactivated by hydrolysis or modification. One of the most important weapons in the armoury of ''Acinetobacter'' is its impressive genetic plasticity, facilitating rapid genetic mutations and rearrangements as well as integration of foreign determinants carried by mobile genetic elements. Of these, insertion sequences are considered one of the key forces shaping bacterial genomes and ultimately evolution.

AbaR resistance islands

Pathogenicity islands, relatively common genetic structures in bacterial pathogens, are composed of two or more adjacent genes that increase a pathogen's virulence. They may contain genes that encode toxins, coagulate blood, or as in this case, allow the bacteria to resist antibiotics. AbaR-type resistance islands are typical of drug-resistant ''A. baumannii'', and different variations may be present in a given strain. Each consists of a transposon backbone of about 16.3 Kb that facilitates horizontal gene transfer. This makes horizontal gene transfer of this and similar pathogenicity islands more likely because, when genetic material is taken up by a new bacterium, the transposons allow the pathogenicity island to integrate into the new microorganism's genome. In this case, it would grant the new microorganism the potential to resist certain antibiotics. Antibiotic resistance genes are commonly transferred between Gram-negative bacteria through plasmids via conjugation, which accelerates the appearance of new resistant strains. AbaR's contain several genes for antibiotic resistance, all flanked by insertion sequences. There exist several resistance genes circulating along ''A. baumannii'' that can be clustered in replicon groups, and may be transferred from the extensively drug-resistant ''Acinetobacter baumannii'' (XDR- AB) and New Delhi Metallo-beta-lactamase-1-producing ''Acinetobacter baumannii'' (NDM- AB) to environmental isolates of ''Acinetobacter'' spp. Conjugation experiments demonstrated that the ''blaOXA-23'', ''blaPER-1'', and ''aphA6'' genes could be successfully transferred between the clinical and the environmental isolates via the plasmid group GR6 or class 1 integrons through in vitro conjugation. In collaboration with some other genes, they provide resistance to aminoglycosides, aminocyclitols, tetracycline, and chloramphenicol.

Efflux pumps

Efflux pumps are protein machines that use energy to pump antibiotics and other small molecules that get into the bacterial cytoplasm and the periplasmic space out of the cell. By constantly pumping antibiotics out of the cell, bacteria can increase the concentration of a given antibiotic required to kill them or inhibit their growth when the target of the antibiotic is inside the bacterium. ''A. baumannii'' is known to have two major efflux pumps which decrease its susceptibility to antimicrobials. The first, AdeB, has been shown to be responsible for aminoglycoside resistance. The second, AdeDE, is responsible for efflux of a wide range of substrates, including tetracycline, chloramphenicol, and various carbapenems. Many other efflux pumps have been implicated in ''A. baumannii'' resistant strains.

Small RNA

Bacterial small RNAs are noncoding RNAs that regulate various cellular processes. Three sRNAs, AbsR11, AbsR25, and AbsR28, have been experimentally validated in the MTCC 1425 (ATCC15308) strain, which is a (multidrug-resistant) strain showing resistance to 12 antibiotics. AbsR25 sRNA could play a role in the efflux pump regulation and drug resistance.

Beta-lactamase

''A. baumannii'' has been shown to produce at least one beta-lactamase, which is an enzyme responsible for cleaving the four-atom lactam ring typical of beta-lactam antibiotics. Beta-lactam antibiotics are structurally related to penicillin, which inhibits synthesis of the bacterial cell wall. The cleaving of the lactam ring renders these antibiotics harmless to the bacteria. ''A. baumannii'' have been observed to express beta-lactmases known as ''Acinetobacter-''derived cephalosporinases (ADCs), which are class C beta-lactamases. In addition, the beta-lactamase OXA-51, a class D beta-lactamase, has been observed in ''A. baumannii'', found to be flanked by insertion sequences, suggesting it was acquired by horizontal gene transfer.

Biofilm formation

''A. baumannii'' has been noted for its apparent ability to survive on artificial surfaces for an extended period of time, therefore allowing it to persist in the hospital environment. This is thought to be due to its ability to form biofilms. For many biofilm-forming bacteria, the process is mediated by flagella. However, for ''A. baumannii'', this process seems to be mediated by pili. Further, disruption of the putative pili chaperone and usher genes ' and ' were shown to inhibit biofilm formation. The formation of biofilms has been shown to alter the metabolism of microorganisms within the biofilm, consequently reducing their sensitivity to antibiotics. This may be because fewer nutrients are available deeper within the biofilm. A slower metabolism can prevent the bacteria from taking up an antibiotic or performing a vital function fast enough for particular antibiotics to have an effect. They also provide a physical barrier against larger molecules and may prevent desiccation of the bacteria. In general, biofilm formation has been linked so far with BfmRS TCS (two-component system) regulating Csu pili, Csu expression regulated by the GacSA TCS, biofilm-associated proteins BapAb, synthesis of the exopolysaccharide poly-β-1,6-N-acetylglucosamine PNAG, acyl-homoserine lactones through AbaR receptor, and AbaI autoinducer synthase. Moreover, inactivation
of ''adeRS'' operon negatively affects biofilm formation and prompts decreased expression of AdeABC. Disruption of abaF has displayed an increase in fosfomycin susceptibility and a decrease in biofilm formation and virulence, suggesting a major role for this pump.

Signs and symptoms of infection

''A. baumannii'' is an opportunistic pathogen with a range of different diseases, each with their own symptoms. Some possible types of ''A. baumannii'' infections include:
* Pneumonia
* Bloodstream infections
* Meningitis
* Wound and surgical site infections, including necrotizing fasciitis
* Urinary tract infections
Symptoms of ''A. baumannii'' infections are often indistinguishable from other opportunistic infections caused by other opportunistic bacteria - including ''Klebsiella pneumoniae'' and ''Streptococcus pneumoniae''.

Symptoms of ''A. baumannii'' infections in turn range from fevers and chills, rash, confusion and/or altered mental states, pain or burning sensations when urinating, strong urge to urinate frequently, sensitivity to bright light, nausea (with or without vomiting), muscle and chest pains, breathing problems, and cough (with or without yellow, green, or bloody mucus). In some cases, ''A. baumannii'' may present no infection or symptoms, as with colonizing an open wound or tracheostomy site.

Treatment

When infections are caused by antibiotic-susceptible Acinetobacter isolates, there may be several therapeutic options, including a broad-spectrum cephalosporin (ceftazidime or cefepime), a combination beta-lactam/beta-lactamase inhibitor (ie, one that includes sulbactam), or a carbapenem (eg, imipenem or meropenem). Because most infections are now resistant to multiple drugs, determining what susceptibilities the particular strain has is necessary for treatment to be successful. Traditionally, infections were treated with imipenem or meropenem, but a steady rise in carbapenem-resistant ''A. baumannii'' has been noted. Consequently, treatment methods often fall back on polymyxins, particularly colistin although tetracyclines have shown promise in MDR ''A. baumannii''. Colistin is considered a drug of last resort because it often causes kidney damage, among other side effects. Prevention methods in hospitals focus on increased hand-washing and more diligent sterilization procedures. An ''A. baumannii'' infection was recently treated using phage therapy. Phages are viruses that attack bacteria, and have also been demonstrated to resensitize ''A. baumannii'' to antibiotics it normally resists.

Scientists at MIT, Harvard's Broad Institute and MIT's CSAIL found a compound named halicin using deep learning that can effectively kill ''A. baumannii''. The compound is a repurposed drug.

Occurrence in veterans injured in Iraq and Afghanistan

Soldiers in Iraq and Afghanistan are at risk for traumatic injury due to gunfire and improvised explosive devices. Previously, infection was thought to occur due to contamination with ''A. baumannii'' at the time of injury. Subsequent studies have shown, although ''A. baumannii'' may be infrequently isolated from the natural environment, the infection is more likely nosocomially acquired, likely due to the ability of ''A. baumannii'' to persist on artificial surfaces for extended periods, and the several facilities to which injured soldiers are exposed during the casualty-evacuation process. Injured soldiers are first taken to level-I facilities, where they are stabilized. Depending on the severity of the injury, the soldiers may then be transferred to a level-II facility, which consists of a forward surgical team, for additional stabilization. Depending on the logistics of the locality, the injured soldiers may transfer between these facilities several times before finally being taken to a major hospital within the combat zone (level III). Generally after 1–3 days, when the patients are stabilized, they are transferred by air to a regional facility (level IV) for additional treatment. For soldiers serving in Iraq or Afghanistan, this is typically Landstuhl Regional Medical Center in Germany. Finally, the injured soldiers are transferred to hospitals in their home country for rehabilitation and additional treatment. This repeated exposure to many different medical environments seems to be the reason ''A. baumannii'' infections have become increasingly common. Multidrug-resistant ''A. baumannii'' is a major factor in complicating the treatment and rehabilitation of injured soldiers, and has led to additional deaths.

Incidence in hospitals

Being referred to as an opportunistic infection, ''A. baumannii'' infections are highly prevalent in hospital settings. ''A. baumannii'' poses very little risk to healthy individuals; however, factors that increase the risks for infection include:
* Having a weakened immune system
* Chronic lung disease
* Diabetes
* Lengthened hospital stays
* Illness that requires use of a hospital ventilator
* Having an open wound treated in a hospital
* Treatments requiring invasive devices like urinary catheters
''A. baumannii'' can be spread through direct contact with surfaces, objects, and the skin of contaminated persons.

The importation of ''A. baumannii'' and subsequent presence in hospitals has been well documented. ''A. baumannii'' is usually introduced into a hospital by a colonized patient. Due to its ability to survive on artificial surfaces and resist desiccation, it can remain and possibly infect new patients for some time. ''A baumannii'' growth is suspected to be favored in hospital settings due to the constant use of antibiotics by patients in the hospital. Acinetobacter can be spread by person-to-person contact or contact with contaminated surfaces. ''Acinetobacter'' can enter through open wounds, catheters and breathing tubes. In a study of European intensive care units in 2009, ''A. baumannii'' was found to be responsible for 19.1% of ventilator-associated pneumonia cases.

References

{{Taxonbar, from=Q3241189

Moraxellaceae
Bacterial diseases
Gram-negative bacteria
Pathogenic bacteria
Bacteria described in 1986